文献速递心脑血管急症重症综合管理与镇静镇痛

早期使用去氨加压素联合血小板输注减少抗血小板治疗相关急性脑出血血肿扩大

Early Administration of Desmopressin and Platelet Transfusion for Reducing Hematoma Expansion in Patients With Acute Antiplatelet Therapy Associated Intracerebral Hemorrhage.
PubMed 文献 · Crit Care Med · 2020-01-01
一句话结论单中心非随机研究显示,对接受抗血小板治疗的急性自发性脑出血患者,60分钟内给予去氨加压素0.4 μg/kg静脉注射联合2 U血小板输注,未能减少血肿扩大或改善3个月功能结局。

该单中心非随机研究纳入2006至2014年间德国图宾根大学医院140例接受抗血小板治疗的急性自发性脑出血成人患者(治疗组72例 vs 对照组68例),干预为脑影像诊断后60分钟内静脉给予去氨加压素(1-去氨基-8-D-精氨酸加压素)0.4 μg/kg联合血小板输注2 U。主要终点为基线至随访CT的相对血肿扩大,两组无差异(中位数8.5% vs 9.1%,p=0.825);血肿扩大≥33%的发生率两组相似(p=0.981);继发性脑室内出血、脑积水及血栓栓塞事件发生率两组相似;3个月功能结局(改良Rankin量表)与治疗无关(校正OR 1.570,95%CI 0.721-3.419,p=0.309)。作者认为,与随机对照PATCH试验一致,早期血小板输注对抗血小板治疗相关脑出血无止血疗效,去氨加压素亦无获益。

要点

  • 接受抗血小板治疗的急性自发性脑出血患者,60分钟内静脉去氨加压素0.4 μg/kg联合血小板2 U输注,总血肿扩大无差异(中位数8.5% vs 9.1%,p=0.825)。
  • 血肿扩大≥33%的发生率两组相似(p=0.981),其中治疗组16例(52%) vs 对照组15例(48%)发生该程度扩大。
  • 继发性脑室内出血、脑积水及出院前血栓栓塞事件发生率两组相似。
  • 3个月功能结局(改良Rankin量表)与去氨加压素联合血小板输注无关(校正OR 1.570,95%CI 0.721-3.419,p=0.309)。
  • 作者认为,与PATCH随机试验一致,早期血小板输注对抗血小板治疗相关脑出血无止血疗效,去氨加压素亦无获益。

适用人群与场景

  • 接受抗血小板治疗的急性自发性脑出血成人患者,且具备24±12小时随访CT。
  • 排除其他脑出血病因、抗凝治疗、凝血功能障碍或基线CT后立即手术的患者。
  • 单中心研究,设置于德国图宾根大学医院。

处置流程与药物剂量

  • 在脑影像诊断抗血小板治疗相关脑出血后60分钟内,静脉给予去氨加压素(1-去氨基-8-D-精氨酸加压素)0.4 μg/kg联合血小板输注2 U。

研究设计与关键结果

  • 单中心非随机研究,2006至2014年纳入140例接受抗血小板治疗的急性自发性脑出血成人患者,治疗组72例 vs 对照组68例。
  • 主要终点相对血肿扩大(基线至随访CT)两组无差异:治疗组中位数8.5%(四分位距12.4) vs 对照组9.1%(四分位距16.5),p=0.825。
  • 脑实质内血肿扩大治疗组10.7%(四分位距23.1) vs 对照组9.2%(四分位距20.7),p=0.900;脑室内血肿扩大治疗组14.5%(四分位距63.2) vs 对照组6.1%(四分位距40.4),p=0.304。
  • 血肿扩大≥33%的发生率两组相似(p=0.981),治疗组16例(52%) vs 对照组15例(48%)。
  • 继发性脑室内出血、脑积水及出院前血栓栓塞事件发生率两组相似。
  • 3个月功能结局(改良Rankin量表)与治疗无关:校正OR 1.570(95%CI 0.721-3.419,p=0.309)。
  • 症状发作至基线CT时间(小时,中位数[四分位距])治疗组3[4] vs 对照组5[5],p=0.468;随访CT时间治疗组26[18] vs 对照组19[12],p=0.352。

证据类型、等级与局限

  • 证据类型:单中心非随机研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,与PATCH随机试验一致,早期血小板输注对抗血小板治疗相关脑出血无止血疗效。
  • 作者认为,与临床前及非脑出血临床研究结果相反,辅助去氨加压素在限制血肿扩大或改善功能结局方面无获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To investigate the hemostatic efficacy of combined desmopressin (1-deamino-8-D-arginine vasopressin) and platelet transfusion in reducing hematoma expansion in acute, spontaneous intracerebral hemorrhage under antiplatelet treatment.

DESIGN: Single-center, nonrandomized study, performed between 2006 and 2014.

SETTING: Tertiary University Hospital of Tuebingen, Germany.

PATIENTS: Adult patients with intracerebral hemorrhage under antiplatelet treatment and follow-up CT at 24 ± 12 hours were included. Exclusion criteria included other intracerebral hemorrhage causes, anticoagulation, coagulopathy, or immediate surgery after baseline-CT.

INTERVENTIONS: Treatment with IV 1-deamino-8-D-arginine vasopressin (0.4 µg/kg) + platelet transfusion (2 U) within 60 minutes of intracerebral hemorrhage under antiplatelet treatment diagnosis on brain imaging.

MEASUREMENTS AND MAIN RESULTS: Primary outcome was relative hematoma expansion from baseline to follow-up CT. Secondary outcomes included secondary intraventricular hemorrhage or hydrocephalus upon follow-up CT, thromboembolic events before discharge, and the 3-month functional outcome (assessed by modified Rankin Scale). One-hundred forty patients were included, 72 treated versus 68 controls. Times of symptom-onset-to-baseline-CT (hr) (median [interquartile range]: 3 [4] vs 5 [5]; p = 0.468) and follow-up CT (26 [18] vs 19 [12]; p = 0.352) were similar between groups. No between-group differences of total intracerebral hematoma expansion (%) (median [interquartile range]: 8.5 [12.4] vs 9.1 [16.5]; p = 0.825), intraparenchymal (10.7 [23.1] vs 9.2 [20.7]; p = 0.900), and intraventricular hematoma expansion (14.5 [63.2] vs 6.1 [40.4]; p = 0.304) were noted. Among patients with hematoma expansion greater than or equal to 33% compared with baseline, 16 (52%) received treatment versus 15 (48%) controls. The occurrence of hematoma expansion greater than or equal to 33% was similar between groups (p = 0.981). Rates of secondary intraventricular hemorrhage, hydrocephalus, and thromboembolic events were similar between groups. Treatment with 1-deamino-8-D-arginine vasopressin + platelet transfusion was not associated with the 3-month functional outcome (adjusted odds ratio, 1.570; 95% CI, 0.721-3.419; p = 0.309).

CONCLUSIONS: In line with the randomized Platelet Transfusion Versus Standard Care After Acute Stroke Due to Spontaneous Cerebral Hemorrhage Associated With Antiplatelet Therapy trial, our results suggest no hemostatic efficacy of early platelet transfusion in intracerebral hemorrhage under antiplatelet treatment. Contrary to results of preclinical and clinical nonintracerebral hemorrhage studies, adjunct 1-deamino-8-D-arginine vasopressin showed no benefit in limiting hematoma expansion or improving functional outcome.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Mengel A, Stefanou MI, Hadaschik KA, et al. Early Administration of Desmopressin and Platelet Transfusion for Reducing Hematoma Expansion in Patients With Acute Antiplatelet Therapy Associated Intracerebral Hemorrhage. Crit Care Med. 2020. PMID: 32304415. doi:10.1097/CCM.0000000000004348

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。